Gilead’s Indian Covid-19 drug licensees to set own prices
US biopharmaceutical company Gilead will allow Indian-basedlicensed manufacturers to set their own prices for the potential
Covid-19vaccine remdesivir, it has been reported.
The rest of this document is only available to i-law.com online
If you are already a subscriber, please enter your details below to log in.